Neurocrine Biosciences Enters Metabolic Market with $2.9 Billion Cash Acquisition of Soleno Therapeutics

Neurocrine Biosciences enters the metabolic market with a $2.9 billion buyout of Soleno Therapeutics, securing the first approved Prader-Willi syndrome drug.

By: AXL Media

Published: Apr 7, 2026, 5:26 AM EDT

Source: Information for this report was sourced from Reuters

Strategic Expansion into Metabolic Rare Diseases

Neurocrine Biosciences announced on Monday a definitive agreement to acquire Soleno Therapeutics in an all-cash transaction valued at $2.9 billion. This acquisition represents a major pivot for the California-based drugmaker, moving beyond its traditional focus on neuroscience to establish a foothold in the metabolic disease landscape. The centerpiece of the deal is Vykat XR, a recently approved medication designed to manage hyperphagia—a condition of extreme, persistent hunger—in patients with Prader-Willi syndrome. By absorbing Soleno’s portfolio, Neurocrine effectively bypasses the lengthy development cycles of its own preclinical obesity candidates, opting instead for a commercially viable asset with established regulatory clearance.

Financial Terms and Market Valuation

Under the terms of the agreement, Neurocrine will pay $53 per share for Soleno, representing a 34% premium over the company’s most recent closing price. Following the announcement, Soleno’s stock surged by more than 33% in premarket trading as investors reacted to the significant valuation boost. Neurocrine has stated that the acquisition will be funded primarily through cash on hand, supplemented by a modest amount of prepayable debt. The transaction is expected to finalize within the next 90 days, pending standard closing conditions and regulatory approvals, at which point Soleno’s operations will be fully integrated into Neurocrine’s rare-disease division.

Revenue Projections for Vykat XR

Analysts have identified Vykat XR as a high-growth asset with substantial long-term revenue potential. In 2025, the drug generated approximately $190 million in sales during its first nine months on the market following a March approval. For the current fiscal year, BMO Capital Markets projects that the treatment will bring in $450 million, with global sales estimated to exceed $2 billion by the mid-2030s. This steady growth trajectory provides Neurocrine with a reliable revenue stream as it scales its metabolic presence, offering what experts describe as a "more sensible" entry point into the sector than competing in the crowded general obesity market.